GlassScriptPhysician profile
Chrystal Means
NPI 1497710180
$7,959.19
in general payments reported to CMS, 2019-2025
48 companies · $1,696 in 2025
The $1,696 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $196 · 2022: $1,608 · 2023: $1,786 · 2024: $2,673 · 2025: $1,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,130 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,130.10 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,139.03 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $1,116.29 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $889.17 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $863.84 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $626.64 | 2022-2025 | |
| Glaxosmithkline, LLC. | $375.09 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $249.38 | 2022-2025 | Jardiance, Synjardy, Tradjenta |
| Janssen Pharmaceuticals, INC | $226.16 | 2021-2024 | Spravato |
| Amgen INC. | $212.92 | 2023-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $212.47 | 2022-2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.21 | 2022-2025 | Xifaxan |
| Vanda Pharmaceuticals INC. | $160.43 | 2024-2025 | Fanapt, Hetlioz |
| Astellas Pharma US INC | $147.66 | 2022-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $135.52 | 2021-2024 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.60 | 2024-2025 | Caplyta |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chrystal Means listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.